Committee News

Harry Sokol is a prominent gastroenterologist at Saint Antoine Hospital and Sorbonne Université and the President of the French Group of Faecal Microbiota Transplantation. In this edition of the ECCO Interview Corner, Professor Sokol shares his journey into gastroenterology, his pioneering work on Inflammatory Bowel Disease (IBD) and the gut microbiome and his vision for the future research.

Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease: 2 Randomized Phase 3 Trials Hanauer SB, Sands BE, Schreiber S, et al. Gastroenterology 2024.

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly-diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial Noor NM, Lee JC, Bond S, et al. Lancet Gastroenterol Hepatol 2024;9:415-427.

Continuous monitoring of CRP, IL-6, and calprotectin in Inflammatory Bowel Disease using a perspiration-based wearable device Shahub S, Kumar RM, Lin KC, et al. Inflamm Bowel Dis 2024 Mar 23; doi: 10.1093/ibd/izae054. Online ahead of print.

Dear Y-ECCO Friends, As we move into the final quarter of the year, this is the perfect time to reflect on our collective achievements and to set our sights on the exciting events that lie ahead.

The first ECCO Global Grant was awarded at ECCO'24 to an international group leading a fascinating prospective study across Sub-Saharan Africa1. The study is focusing on IBD genetics in the region and is being led by Professor Nick Croft and Dr. Phoebe Hodges from Queen Mary University of London, Professor Paul Kelly and colleagues from the Tropical Gastroenterology and Nutrition Group, University of Zambia and Professor McGovern and his group at Cedars-Sinai, Los Angeles. I had the privilege of discussing aspects of the study with members of the study consortium.

During the last ECCO’24 Congress in Stockholm, the ECCO Governing Board announced the new strategy REACH. The REACH strategy is the acronym of five clear goals to shape the current and future ECCO activities for the next years, better defining and expanding ECCO global mission to improve the care for all IBD patients...

Change is the engine that propels scientific progress, and within this dynamic, committees evolve. As members transition, embracing fresh perspectives, the spirit of innovation flourishes, shaping the path ahead. Amidst this journey, EpiCom is pleased to introduce Paul Henderson while bidding farewell to Julien Kirchgesner.

Two new members joined the N-ECCO Committee in February 2024: Maria de Jong from the Netherlands and Cathy Walsh from Ireland. We all share the same mission: promoting IBD nursing in Europe, rolling out educational and research programmes, and developing patient care and education. We are looking forward to working together, and here Maria and Cathy introduce themselves and their aims while on the committee...

Diet in Inflammatory Bowel Disease has become a hot topic in recent years, pushed forward by advances in our understanding of the microbiome and the promise of nutrition as therapy, particularly in Crohn’s Disease. One of the most important questions in clinic (and yet the hardest to answer) remains “What can I eat?” or variations of the same. The reason this question is so difficult to answer is the enormous complexity in how diet overlays IBD and also the lack of high-quality scientific studies addressing this specific problem...

Caroline Nordenvall has recently joined the S-ECCO Committee. She works at the Karolinska University Hospital as an IBD surgeon and is head of the research group in colorectal surgery. She is an Associate Professor within the University. Caroline is the PI of the CRUISE study (Colectomy and Reconstruction in Ulcerative colitis In Sweden and England study), a multicentre study in collaboration with three Swedish centres and St Marks Hospital (England). This is a clinical preference study that has the aim of comparing QoL and functional outcome following restorative surgery with ileal pouch ...

The last decade has seen a dramatic increase in drugs available for the treatment of IBD. However, each of these novel biologics or small molecules achieves disease remission in only a relatively small proportion of patients [1].To date, implementation in clinical practice of evidence that assists in better evaluating the chance of therapy success in a particular patient for a particular drug is limited. Therefore, when choosing a drug for a patient with IBD who is starting therapy or needs to switch drugs, a trial-and-error approach may be unavoidable.

Combination therapy with anti-TNF inhibitors (ATI) and immunomodulator (IMM) therapy remains an efficacious treatment strategy for disease control in moderate to severe Inflammatory Bowel Disease (IBD). This conclusion was largely based on the findings of landmark trials, SONIC and UC SUCCESS, which showed combination therapy to be far superior to monotherapy in achieving durable clinical and endoscopic remission in IBD [1, 2]...

The gut microbiota of patients with Inflammatory Bowel Disease (IBD) may have a role in disease aetiology and course [1]. Patients with IBD often have dysbiotic microbiota, with lower microbial diversity and cell counts, with both absolute and relative abundance of commensal microorganisms [2, 3]. Conversely, during remission following anti-inflammatory therapy, the gut microbiota has been observed to shift to a more eubiosis-like composition [3–6]. Furthermore, lower proportions of taxa with pro-inflammatory properties and mucus-degrading bacteria, as well as higher proportions of short-chain

Adalimumab is an effective and safe treatment for Crohn’s Disease (CD). However, both patients and healthcare professionals may wish to mitigate medication exposure due to potential safety and economic concerns in the long term. Since a high relapse rate follows drug discontinuation, treatment de-escalation without actually stopping the medication may allow for decreasing drug exposure while maintaining efficacy. In two observational studies, de-escalation from a 2-week to a 3-week adalimumab dosing interval was successful in most of the patients, though reversal to a 2-week dosing interval...

Dear Y-ECCO Enthusiasts! Can you believe that it’s been only four months since the last ECCO Congress? I bet that many of you are already knee-deep in exciting research for ECCO 2025 in Berlin, so mark your calendars and keep an eye open for the abstract submission deadline. You can’t miss that, as we want to see your top-notch research! Maybe you are the next Y-ECCO Best Abstract awardee!

For this Y-ECCO Interview Corner we met with Shaji Sebastian, who is known to everyone as Seb, on the Friday of the ECCO Congress. Seb has had a long association with ECCO. He is the outgoing Chair of ClinCom and was elected as Treasurer of ECCO at this year’s General Assembly. He is a consultant in Hull in the North of England, having got there through a somewhat circuitous route, as we will hear...

The SONIC trial yielded seminal findings showing that the combination of infliximab and azathioprine is more effective than either treatment alone for the maintenance of remission in patients with Crohn’s Disease (CD) [1]. In recent years, despite the availability of an increasing number of biologics and small molecules to treat CD, a ceiling of therapeutic efficacy has been reached [2]. Therefore, there has been a resurgence of interest in whether this therapeutic ceiling “effect” can be overcome with new treatment combinations.

Despite an expanding therapeutic arsenal, a considerable proportion of patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) fail to achieve or sustain therapeutic responses [1, 2]. Mechanisms contributing to this failure, particularly with respect to biologic therapy, are only partially understood [3]. Uncovering the mechanisms behind loss of response may help to enhance the efficacy of existing treatment options or to develop alternative options for the future.

Patients will often ask, “What causes Inflammatory Bowel Disease?” Frustratingly, we remain unable to answer this seemingly simple question, beyond the often-quoted paradigm that unknown environmental factors trigger inflammation in genetically susceptible individuals. Although our understanding of the immune response in IBD has reached phenomenally detailed levels of resolution, the nature and identity of the initial environmental triggers of IBD have continued to remain a mystery.